Debra BorchardtMarch 2, 2018
InMed Pharmaceuticals
InMed Pharmaceuticals Inc. (IMLFF) announced that it has received conditional approval from the Toronto Stock Exchange to list its common shares on the TSX. Final approval of the listing on the TSX remains subject to InMed fulfilling certain customary listing conditions of the TSX on or before the TSX-imposed deadline of May 29, 2018. The shares will continue to trade under the symbol ‘IN’.
CannTrust Holdings
CannTrust Holdings Inc. announced that its shares will begin trading on the Toronto Stock Exchange on Monday, March 5, 2018. Shares will continue to trade with the symbol “TRST”. The common shares will be delisted from the CSE, effective close of trading on Friday, March 2, 2018. “Graduating to the TSX reflects the amazing progress we have made since listing on the CSE in August last year and represents yet another important milestone for CannTrust as we continue our successful journey as one of Canada’s leading cannabis companies,” said Eric Paul, Chief Executive Officer of CannTrust.
Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. (ATTBF) announced it has completed its acquisition of a 90% ownership interest in Gabriola Green Farms Inc. Gabriola is a British Columbia company that has applied to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations on Gabriola Island. The company said in a statement that Gabriola Island has a consistent temperature and humidity level, which makes it well suited to greenhouse growing. “We are excited to complete our acquisition of Gabriola. Gabriola’s anticipated LP will complete our suite of downstream offerings and be the highlight of our growth into a full-service cannabis company,” stated Rob Abenante, Abattis President, and CEO.
Cannabis Consortium Inc.
Bahamas Development Corporation (BDCI) subsidiary company Cannabis Consortium, Inc., has partnered with a group that will own a percentage of a Pre-ICO marijuana dispensary. Pre-ICO means medical dispensaries that were open before September 14, 2007. ICO refers to a Los Angeles city ordinance that prohibited new dispensaries from opening and kept the existing ones open if they registered with the city. The dispensary currently operates in an under 1,000 square foot and is relocating to an 8,000 square foot, facility. The new dispensary has current licenses for Retail, Manufacturing, and Cultivation.
Insys Therapeutics Inc.
Insys Therapeutics, Inc. (INSY), announced the initiation of Phase 3 clinical trial to study a cannabidiol oral solution for the treatment of infantile spasms, a rare type of pediatric epilepsy that occurs in very young children. “We need better treatments for infantile spasms, one of the more severe and dangerous seizure disorders of early childhood,” said Shaun Hussain, M.D., a pediatric neurologist at UCLA Mattel Children’s Hospital and director of its Infantile Spasms Project. “That’s why we’re excited about this pivotal study, which has the potential to reveal a new piece of the treatment puzzle for infantile spasms.” The stock jumped almost 5% on the news and was lately trading at $7.68.
